Abstracts tagged "autoimmune diseases"

Abstract Number: 1127 • ACR Convergence 2024
Risk of Ocular Inflammatory Conditions in Patients with Autoimmune Diseases: A Retrospective Study Using the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Autoimmune diseases are known to cause various ocular inflammatory conditions and are often the initial presentation in many of these diseases. This study aims…
Abstract Number: 1414 • ACR Convergence 2024
Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations
Robert Fox¹, Anahita Deboo², Matthew Baker³, Stamatina Danielides⁴, Eduardo de Sousa⁵, Julie Frantsve Hawley⁶, Brent Goodman⁷, Katherine Hammitt⁶, Jennifer King⁸, Matt Makara⁶, Steven Mandel⁹, Ghaith Noaiseh¹⁰, Pantelis Pavlakis¹¹, George Sarka¹², Arun Varadhachary¹³, Daniel Wallace¹⁴, Robert Hal Scofield¹⁵, Nancy Carteron¹⁶ and Steven Carsons¹⁷, ¹Rheumatology Clinic, San Diego, CA, ²Temple University, Philadelphia, ³Stanford University, Menlo Park, CA, ⁴Vcu, Glen Allen, VA, ⁵Mercy, Moore, OK, ⁶Sjogren's Foundation, Reston, VA, ⁷Mayo Clinic, Scottsdale, AZ, ⁸UCLA, Los Angeles, CA, ⁹Hofstra, Hempstead, ¹⁰University of Kansas Medical Center, Kansas City, KS, ¹¹Hospital for Special Surgery, New York, NY, ¹²UCLA, Laguna Hills, CA, ¹³Washington University in St. Louis, St. Louis, MO, ¹⁴Cedars Sinai Medical Center, Studio City, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of California, Berkeley & San Francisco, Angwin, CA, ¹⁷NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Peripheral Nervous System (PNS) manifestations occur frequently in Sjögren’s disease and can encompass mononeuropathy, polyneuropathy, and autonomic neuropathy. Guidance is needed for rheumatologists, neurologists,…
Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Maria-Grazia Lazzaroni¹, Paolo Baggi², Liala Moschetti¹, Eleonora Pedretti³, Elda Piovani¹, Claudia Barison¹, Emma Manzoni⁴, Franco Franceschini¹, Stefano Bonardelli² and Paolo Airò¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Vascular Surgery Unit, ASST Spedali Civili of Brescia, University of Brescia, Italy, Brescia, Italy, ³Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…
Abstract Number: 1692 • ACR Convergence 2024
Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease
Trinitee Oliver¹, Kim Taylor², Ye Cao³, Takanori Sasaki⁴, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin⁶ and Richard Ainsworth⁶, ¹Cedars-Sinai Medical Center, Hawthorne, CA, ²University of California, San Francisco, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: B-cell subsets display aberrant function in systemic sclerosis (SSc) pathogenesis and infiltrate the lungs of SSc patients with interstitial lung disease (ILD). B-cells relevance…
Abstract Number: 1825 • ACR Convergence 2024
Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis
Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
Abstract Number: 1887 • ACR Convergence 2024
High Rates of Cost-Related Medication Non-Adherence Among Younger Patients Receiving Immunosuppression Are Exacerbated by Other Chronic Conditions
Samuel Good¹, Bryant England² and Elizabeth Volkmann³, ¹University of California, Los Angeles, Los Angeles, CA, ²University of Nebraska Medical Center, Omaha, NE, ³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Medication non-adherence is associated with worse autoimmune disease outcomes; however, it is unknown whether adherence rates related to cost barriers differ across diseases and…
Abstract Number: 2034 • ACR Convergence 2024
Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease
Anne Dupont¹, Clairelyne Dupin², Esther Ebstein¹, Marine Forien¹, Sébastien Ottaviani¹, Pierre Le Guen², Quentin Philippot², Raphaël Borie², Bruno Crestani³, Philippe Dieudé¹ and Pierre-Antoine Juge⁴, ¹Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ²National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, France, ³National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, ⁴Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA
Background/Purpose: Interstitial lung diseases (ILD) are severe manifestations of systemic autoimmune diseases (SARD) that are associated with an increased mortality. Although the primary endpoint was not…
Abstract Number: 2258 • ACR Convergence 2024
The Window of Opportunity: A Concept Also Applicable to Undifferentiated Arthritis
Patricia Quiroga Colina¹, María Paula Álvarez², Maryia Nikitsina³, Marina Dueñas⁴, Juan Carlos Sáez⁵, Cristina Valero⁶, Jesus A García-Vadillo⁷, María Ahijón Lana³, Santos Castañeda⁸, Eva Tomero Muriel⁹, Esther Vicente-rabaneda⁸, Ana Romero⁵, Irene Llorente⁵, Miren Uriarte-Ecenarro⁵, Rosario García-Vicuña², Ana Ortiz⁸ and Isidoro González-Álvaro³, ¹Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ²Hospital Universitario de La Princesa, Madrid, Madrid, Spain, ³University Hospital La Princesa, Madrid, Madrid, Spain, ⁴Servicio de Reumatología Hospital La Princesa, Madrid, Madrid, Spain, ⁵H.U.La Princesa, Madrid, Spain, ⁶Hospital de la Princesa, Madrid, Spain, ⁷H La Princesa, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹La Princesa Hospital, Madrid, Madrid, Spain
Background/Purpose: The window of opportunity is well established in patients with rheumatoid arthritis (RA) but it is unclear in patients with undifferentiated arthritis (UA). This study…
Abstract Number: 2457 • ACR Convergence 2024
Polypharmacy, Drug-drug Interactions, and Adverse Drug Reactions Among Systemic Sclerosis Patients: A Cross-sectional Risk Factor Study
Sara Boukhlal¹, Laurent Chouchana², Malika Saadi³, marion Casadevall¹, Pascal cohen⁴, bertrand Dunogue⁵, Anne Murarasu¹, Alexis Régent⁶, Luc Mouthon⁵ and Benjamin Chaigne⁷, ¹AP HP, paris, France, ²Cochin, Paris, France, ³Cardiology Department - Cochin Hospital, Paris, France, ⁴National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁷Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence…
Abstract Number: 2603 • ACR Convergence 2024
A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation
Gregg Silverman¹ and Laurence Morel², ¹NYU Grossman School of Medicine, New York, NY, ²Joe R. & Teresa Lozano Long School of Medicine, San Antonio, TX
Background/Purpose: The mechanisms by which the gut microbiome contributes to autoimmune pathogenesis remain poorly understood. In lupus patients, more than ten-fold blooms of Ruminococcus gnavus…
Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Elizabeth Garner, George Kwong, Tristan W Fowler, Heinrich Kufeldt, Brian Kerfs, Julie Kim, Art Aviles, Lynne Alexander, Franco Davi, Chris Holland, Jean-Yves Maziere, Ashraf Garrett, Mara Bryan, Linh Chu, Sarbani Bhaduri, Michele Gerber, Elaine Alambra, Justin Skoble, Tom Kochy, Tonia Nesheiwat, Socorro Portella, Enrique Zudaire and Steven B Kanner, Caribou Biosciences, Berkeley, CA
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 0300 • ACR Convergence 2024
Evaluation of Long-term Primary Patency of Iliocaval Stenting in Patients with Retroperitoneal Fibrosis/chronic Periaortitis
Raymond Lay¹, Sara Achenbach², Cynthia Crowson¹, Umar Ghaffar¹, Michelle Burke¹, Haraldur Bjarnason¹, Newton Neidert¹, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Idiopathic retroperitoneal fibrosis (RPF) / chronic periaortitis (CP) is an uncommon condition characterized by a fibroinflammatory periarterial soft tissue thickening around the infra-renal abdominal…
Abstract Number: 0429 • ACR Convergence 2024
Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Rashmi Dhital¹, Kerri Bertrand², Essi Heinonen³ and Christina Chambers⁴, ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, CA, ³UC San Diego, La Jolla, CA; Karolinska Institutet, Stockholm, Sweden, San Diego, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic inflammation in autoimmune rheumatic diseases (ARDs) may alter human milk composition, akin to changes observed in other inflammatory states, indirectly impacting infant health,…
Abstract Number: 0658 • ACR Convergence 2024
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
Richard Furie¹, Amit Saxena², Samir Parikh³, Richard Leff⁴, Lucas Bohnett⁵, Kathryn Ray⁶, Brian Tuch⁴, Janet Anderl⁴, Jennifer Whang⁴ and Kiruthi Palaniswamy⁷, ¹Northwell Health, Manhasset, NY, ²NYU School of Medicine, New York, NY, ³Ohio State University, Columbus, OH, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Kezar Life Sciences, El Cajon, ⁶Kezar Life Sciences, Mill Valley, CA, ⁷Kezar Life Sciences, Inc, South San Francisco, CA
Background/Purpose: Zetomipzomib is a selective inhibitor of the immunoproteasome with anti-inflammatory and immunomodulatory potential without evidence of immunosuppression to date. The MISSION study (NCT03393013), a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].